Evidence Hub

Moxifloxacin-induced insomnia with psychotic episodes in a toddler: a case report

Getova-Kolarova V, Hababa-Ivanova I, Georgieva N

European journal of hospital pharmacy : science and practice, 2026

1 citation

Abstract

Moxifloxacin is a fourth-generation fluoroquinolone with a broad spectrum of antibacterial activity. It is commonly used for both local and systemic applications. Data on the safety profile of fluoroquinolones indicate the potential for serious adverse reactions including neurological and psychiatric disturbances. The current case describes the off-label use of moxifloxacin eye drops for nasal administration in a toddler which led to insomnia and symptoms of severe psychosis. Notably, these adverse events resolved completely shortly after discontinuation of treatment. This case highlights a rare and potentially debilitating adverse reaction and underscores the critical importance of clinical judgement when prescribing off-label medicines in the paediatric population.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free